Vitamin A or zymosan pretreatment attenuates alpha-naphthylisothiocyanate-induced liver injury.
alpha-Naphthylisothiocyanate (ANIT) is a cholangiolitic hepatotoxicant that causes periportal hepatic injury in the rat that is neutrophil- and platelet-dependent. Since macrophages have recently been implicated as participants in some chemically induced hepatotoxicities, we evaluated the role of these cells in ANIT-induced hepatic injury. Rats were treated with gadolinium chloride (GdCl3), an agent which decreases hepatic macrophage numbers and activity, zymosan, an agent which increases hepatic macrophage numbers, or vitamin A, which increases hepatic macrophage activity. GdCl3 did not ameliorate ANIT-induced hepatotoxicity, as demonstrated by a lack of attenuation of any of the markers of hepatic insult evaluated. In contrast, pretreatment with either zymosan or vitamin A decreased ANIT hepatotoxicity. Zymosan administration reduced blood neutrophil numbers and influx of neutrophils into the peritoneum after intraperitoneal glycogen administration but did not affect hepatic neutrophil accumulation in ANIT-treated rats. To determine if macrophages were important in the protection by vitamin A, rats were cotreated with GdCl3 and vitamin A. GdCl3 did not alter the protection from ANIT hepatotoxicity afforded by vitamin A. Vitamin A treatment decreased ANIT and glutathione concentrations in bile at 1 and 4 hr after ANIT administration but had a minimal effect on plasma ANIT concentration. In summary, pretreatment of rats with zymosan or vitamin A but not GdCl3 attenuated ANIT-induced liver injury. The protection afforded by zymosan may derive from its effects on neutrophils or platelets. The protection by vitamin A appears to result from its effect on the transport of ANIT into bile. The results suggest that hepatic macrophages are not required for the manifestation of ANIT hepatotoxicity.
Bailie
M B
MB
Department of Pharmacology and Toxicology, Michigan State University, East Lansing 48824, USA.
Jean
P A
PA
Lappin
P B
PB
Scozzaro
M J
MJ
Schmidt
T M
TM
Moulin
F J
FJ
Roth
R A
RA
D015058:1-Naphthylisothiocyanate / Q000037:antagonists & inhibitors* / Q000633:toxicity; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D005682:Gadolinium / Q000494:pharmacology; D006003:Glycogen / Q000494:pharmacology; D007728:Kupffer Cells / Q000187:drug effects / Q000378:metabolism; D007958:Leukocyte Count; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D014801:Vitamin A / Q000008:administration & dosage / Q000494:pharmacology*; D015054:Zymosan / Q000008:administration & dosage / Q000494:pharmacology*
D000893:Anti-Inflammatory Agents; D014801:Vitamin A; D015058:1-Naphthylisothiocyanate; D006003:Glycogen; D015054:Zymosan; D005682:Gadolinium; C038958:gadolinium chloride